Nevertheless, it is encouraging that our studies are complementary in demonstrating the efficacy of PTK6 inhibition in inhibiting the growth of Her2 targeted therapy-resistant breast cancer cells, and future studies are aimed at identifying biomarkers associated with cytostatic vs. cytocidal responses to PTK6 downregulation. This evidence concerns the gene PTK6 and breast carcinoma.